ADXS Advaxis Inc

Advaxis Inc focuses on discovery, development, and commercialization of proprietary Lm (Listeria monocytogenes)-LLO (Listeriolysin O) cancer immunotherapies.

As of 04/13/2021     IEX book   CBOE book

Security Information
Category1:  US Equity
Category2:  Common stocks
Category3:  Micro cap
GICS sector:  Health Care
Industry:  Biotechnology
Index country:  USA
Country of incorporation:  USA
IPO date:  07/28/2005
Outstanding shares:  120,382,668
Average volume:  3,784,725
Market cap:   $68,618,121
Current dividend yield:  0.00%
All SEC filings:     SEC Edgar Online
Quarterly filings:   10-Q
Annual filings:      10-K
CUSIP:    007624307
ISIN:        US0076243072
Sedol:      BJK10R2
Valuation   (See tab for details)
PE ratio:   -6.66
PB ratio:   0.22
PS ratio:   36.79
Return on equity:   -60.12%
Net income %:   -1,211.21%

2021 © Stock Market MBA, Inc. Terms of use | Privacy policy